6
ALL6
AusperBioYear
6
ALL1
20252
20243
2023DEALS // DEV.
6
ALL6
DevelopmentsCountry
6
ALL6
CHINA6
ALL6
InapplicableTherapeutic Area
6
ALL6
Infections and Infectious DiseasesStudy Phase
6
ALL6
Phase IIDeal Type
6
ALL6
InapplicableProduct Type
6
ALL6
OligonucleotideDosage Form
6
ALL6
Subcutaneous InjectionLead Product
6
ALL6
AHB-137Target
6
ALL6
UndisclosedLead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AusperBio Completes Dosing & Unblinding in AHB-137 Phase IIb Trial
Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.
Product Name : AHB-137
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AusperBio Receives Breakthrough Designation for AHB-137 in Chronic Hepatitis B
Details :
Product Name : AHB-137
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 07, 2024
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AusperBio Announces Major Progress in AHB-137 Clinical Development
Details :
Product Name : AHB-137
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AHB-137
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 03, 2023
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment
Details :
Product Name : AHB-137
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 25, 2023
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AusperBio Announces IND Approval from China CDE for HBV ASO AHB-137
Details :
Product Name : AHB-137
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable